<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951195</url>
  </required_header>
  <id_info>
    <org_study_id>VX16-152-102</org_study_id>
    <secondary_id>2016-003049-27</secondary_id>
    <nct_id>NCT02951195</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group,
      multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple
      Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with
      cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function
      (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are
      homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene
      (F508del/F508del).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline up to 8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sweat chloride concentrations</measure>
    <time_frame>from baseline at Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>from baseline at Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in ppFEV1</measure>
    <time_frame>from baseline at Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score</measure>
    <time_frame>from baseline at Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA (μg/mL)</measure>
    <time_frame>Day 1 through Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA (μg.h/mL)</measure>
    <time_frame>Day 1 through Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA (μg/mL)</measure>
    <time_frame>Day 1 through Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF Cohort 1A: Triple Combination (TC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-152 100 milligrams (mg) administered every 12 hours (q12h). TEZ 100 mg once daily (qd). IVA 150 mg q12h.
Morning Dose: VX-152 + TEZ/IVA
Evening Dose: VX-152 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF Cohort 1A: TC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos matched to VX-152, TEZ/IVA, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF Cohort 1B: TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort 1A, if supported by safety and PK Data.
The dosage of VX-152 may be adjusted based on data from Cohort 1A.
Morning Dose: VX-152 + TEZ/IVA
Evening Dose: VX-152 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF Cohort 1B: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos matched to VX-152, TEZ/IVA, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF Cohort 1C: TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort 1B, if supported by safety and PK Data.
The dosage of VX-152 to be determined based on data from Cohort 1B.
Morning Dose: VX-152 + TEZ/IVA
Evening Dose: VX-152 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF Cohort 1C: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos matched to VX-152, TEZ/IVA, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.
The dosage of VX-152 to be determined based on data from Cohort 1A (and from Cohort 1B, if applicable.)
Morning Dose: VX-152 + TEZ/IVA
Evening Dose: VX-152 + IVA
The experimental period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.
Morning Dose: Placebo + TEZ/IVA
Evening Dose: Placebo + IVA
The active comparator period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort 2A, if supported by safety and PK Data.
The dosage of VX-152 to be determined based on data from Cohorts 1A, 1B, and 2B, as applicable.
Morning Dose: VX-152 + TEZ/IVA
Evening Dose: VX-152 + IVA
The experimental period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.
Morning Dose: Placebo + TEZ/IVA Evening Dose: Placebo + IVA
The active comparator period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-152</intervention_name>
    <arm_group_label>Heterozygous F508del/MF Cohort 1A: Triple Combination (TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1B: TC</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1C: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tezacaftor</intervention_name>
    <arm_group_label>Heterozygous F508del/MF Cohort 1A: Triple Combination (TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1B: TC</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1C: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TEZ/IVA</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TEZ/IVA</arm_group_label>
    <other_name>TEZ</other_name>
    <other_name>VX-661</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>Heterozygous F508del/MF Cohort 1A: Triple Combination (TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1B: TC</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1C: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TEZ/IVA</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TEZ/IVA</arm_group_label>
    <other_name>IVA</other_name>
    <other_name>VX-770</other_name>
    <other_name>Kalydeco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple Placebo</intervention_name>
    <arm_group_label>Heterozygous F508del/MF Cohort 1A: TC</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1B: Triple Placebo</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF Cohort 1C: Triple Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for VX-152</intervention_name>
    <arm_group_label>Homozygous F508del/F508del Cohort 2A: TEZ/IVA</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TC</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del Cohort 2B: TEZ/IVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to comply with scheduled visits, treatment pan, study restrictions,
             laboratory tests, contraceptive guidelines, and other study procedures.

          -  Body weight ≥35 kg.

          -  Sweat chloride value ≥ 60 mmol/L from test results obtained during screening.

          -  Subjects must have an eligible CFTR genotype:

               -  Cohorts 1A, 1B, 1C: Heterozygous for F508del and a minimal function mutation
                  known or predicted not to respond to TEZ and/or IVA.

               -  Cohorts 2A, 2B: Homozygous for F508del.

          -  Subjects must have an FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height
             at the Screening Visit.

          -  Stable CF disease as judged by the investigator.

          -  Willing to remain on a stable CF medication regimen through the planned end of
             treatment or if applicable the Safety Follow-up Visit.

        Exclusion Criteria:

          -  History of any comorbidity that in the opinion of the investigator might confound the
             results of the study or pose an additional risk in administering study drug to the
             subject.

          -  History of cirrhosis with portal hypertension.

          -  Risk factors for Torsade de Pointes.

          -  History of hemolysis.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.

          -  Clinically significant abnormal laboratory values at screening.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy for pulmonary disease within 28 days before the first dose of study drug.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  An acute illness not related to CF within 14 days before the first dose of study drug.

          -  A standard digital ECG demonstrating QTc &gt;450 msec at screening.

          -  History of solid organ or hematological transplantation.

          -  History or evidence of cataract or lens opacity determined to be clinically
             significant by the ophthalmologist or optometrist, based on the ophthalmologic
             examination during the Screening Period.

          -  History of alcohol or drug abuse in the past year, including but not limited to,
             cannabis, cocaine, and opiates, as deemed by the investigator.

          -  Ongoing or prior participation in an investigational drug study with certain
             exceptions.

          -  Use of commercially available CFTR modulator within 14 days before screening (applies
             only to Cohorts 1A, 1B, and 1C).

          -  Pregnant or nursing females: Females of childbearing potential must have a negative
             pregnancy test at screening and Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

